Nice find- The Difference between THIS study and Roche's targets is the fact that this is a Generioc form of a successful drug- Zofran- IF Rhuph20 makes injectable form better, Halozyme would wholly own a proprietary combination of a generic- which might exceed 5% revenues of a partnered product.
Pfizer has an IV Ondansetron. This trial started several months before Pfizer deal. Likely this was part of deal and a target. Halo not in the business of manufacturing/marketing. Of course, only speculation.
Both Herceptin and Rituxin can cause nausea after and during infusion. The usual response is a bolus of IV Zofran. It seems this study is simply clearing the way for the SC infusion of these chemo drugs since it would defeat the purpose if one had to start an IV every time a patient developed nausea.
Zofran also comes in a few oral forms but, if you're throwing up, it isn't very helpful. It can be given IM but why stick someone again if they already have SQ access and you can simply push the Zofran/rhuph20 mix?